1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Drugs In Development, 2022, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 14, 138, 145, 3, 13, 60, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 6, 4, 1 and 5 molecules, respectively.
Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Esophageal Cancer - Overview
- Esophageal Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Esophageal Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Esophageal Cancer - Companies Involved in Therapeutics Development
- Esophageal Cancer - Drug Profiles
- Esophageal Cancer - Dormant Projects
- Esophageal Cancer - Discontinued Products
- Esophageal Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Esophageal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Esophageal Cancer - Dormant Projects, 2022
- Esophageal Cancer - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Esophageal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- Affimed GmbH
- AIMM Therapeutics BV
- Akeso Inc
- Alkermes Plc
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Ambrx Biopharma Inc
- amcure GmbH
- Amgen Inc
- AMI Onco Theranostics LLC
- Anaveon AG
- Anhui Anke Biotechnology (Group) Co Ltd
- Anhui Kedgene Biotechnology Co Ltd
- Apexigen Inc
- Apollomics Inc
- Aptacure Therapeutics Ltd
- Arcus Biosciences Inc
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Ascentawits Pharmaceuticals Ltd
- AskGene Pharma Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Atreca Inc
- Aurigene Discovery Technologies Ltd
- AVEO Pharmaceuticals Inc
- Bayer AG
- BeiGene Ltd
- Beijing Biostar Technologies Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- Beijing Scitech-MQ Pharmaceuticals Ltd
- Beijing Weiyuan Likang Biological Technology Co Ltd
- Bexion Pharmaceuticals LLC
- Bicycle Therapeutics Plc
- Bio-Synectics Inc
- BioMed Valley Discoveries Inc
- BioNTech SE
- Biostage Inc
- BioStar Pharmaceuticals Inc
- Biotheus Inc
- Boehringer Ingelheim International GmbH
- BrightGene Bio-Medical Technology Co Ltd
- Bristol-Myers Squibb Co
- CanBas Co Ltd
- Cantargia AB
- CARsgen Therapeutics Ltd
- CDR-Life Inc
- Cedilla Therapeutics
- Celldex Therapeutics Inc
- Centrymed Pharmaceutical Inc
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- Chongqing Precision Biotech Co Ltd
- Chugai Pharmaceutical Co Ltd
- Coherent Biopharma
- Cotinga Pharmaceuticals Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Curegenix Inc
- Curis Inc
- Cyclacel Pharmaceuticals Inc
- Cytlimic Inc
- Cytocraft Bio-Tech Development Co Ltd
- CytomX Therapeutics Inc
- DAE HWA Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Delta-Fly Pharma Inc
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- Dragonfly Therapeutics Inc
- Dyadic International Inc
- Eisai Co Ltd
- Elevation Oncology Inc
- Eli Lilly and Co
- Ella Therapeutics Ltd
- Elucida Oncology Inc
- Ennaid Therapeutics LLC
- Etern BioPharma Co Ltd
- Evopoint Bioscience Co Ltd
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Genentech USA Inc
- GenFleet Therapeutics (Shanghai) Inc
- Genmab AS
- GenoImmune Therapeutics Biotechnology Co Ltd
- Gilead Sciences Inc
- GLG Pharma SA
- GlycoNex Inc
- Glycotope GmbH
- GlyTherix Ltd
- GO Therapeutics Inc
- GSK plc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou Anjie Biomedical Technology Co Ltd
- Guangzhou Saliai Stemcell Science and Technology Co Ltd
- Guangzhou Yinming Biomedical Technology Co Ltd
- Hangzhou Bensheng Pharmaceutical Co Ltd
- Hangzhou Neoantigen Therapeutics Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- HEC Pharma Co Ltd
- Huabo Biopharm (Shanghai) Co Ltd
- Huahui Anjian (Beijing) Biotechnology Co Ltd
- Hualan Biological Engineering Inc
- Hummingbird Bioscience Pte Ltd
- Hutchison MediPharma Ltd
- I-Mab
- Ideaya Biosciences Inc
- Idera Pharmaceuticals Inc
- Immatics NV
- Immix BioPharma Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmuneSensor Therapeutics Inc
- Immunocore Limited
- Immvira Co Ltd
- Incyte Corp
- Inhibrx Inc
- Innate Pharma SA
- Innovative Cellular Therapeutics Co Ltd
- Innovent Biologics Inc
- Inovio Pharmaceuticals Inc
- Ipsen SA
- Istari Oncology Inc
- Jacobio Pharmaceuticals Group Co Ltd
- JenKem Technology Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangxi Qingfeng Pharmaceutical Co Ltd
- Johnson & Johnson
- Keythera Pharmaceuticals Co Ltd
- Kintor Pharmaceutical Ltd
- Kymab Ltd
- Laekna Therapeutics Shanghai Co Ltd
- LaNova Medicines Ltd
- Leap Therapeutics Inc
- Lepu Biopharma Co Ltd
- LEXEO Therapeutics LLC
- LIfT BioSciences Ltd
- Liminatus Pharma LLC
- LipoMedix Pharmaceutical Inc
- Lumosa Therapeutics Co Ltd
- Luye Pharma Group Ltd
- Lycera Corp
- Lyvgen Biopharma Ltd
- MaxiVAX SA
- MedGene Therapeutics Inc
- Medical Guidance Systems LLC
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Merus NV
- Modra Pharmaceuticals BV
- Molecular Templates Inc
- Myeloid Therapeutics Inc
- Nanjing Sanhome Pharmaceutical Co Ltd
- New Beta Innovation Ltd
- NextCure Inc
- NGM Biopharmaceuticals Inc
- NovaRock Biotherapeutics Inc
- Novartis AG
- Novita Pharmaceuticals Inc
- OBI Pharma Inc
- Omeros Corp
- Oncolys BioPharma Inc
- Onconova Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- PDS Biotechnology Corp
- Pfizer Inc
- Pharma Mar SA
- PharmaDrug Inc
- Pieris Pharmaceuticals Inc
- PlantForm Corp
- POINT Biopharma Global Inc
- Precigen Inc
- Prelude Therapeutics Inc
- Privo Technologies Inc
- PsiOxus Therapeutics Ltd
- Puma Biotechnology Inc
- Purple Biotech Ltd
- Qilu Pharmaceutical Co Ltd
- Quadriga BioSciences Inc
- Rafael Pharmaceuticals Inc
- Rakuten Medical Inc
- Rapa Therapeutics LLC
- RAPT Therapeutics Inc
- RaQualia Pharma Inc
- RemeGen Co Ltd
- Repare Therapeutics Inc
- Replimune Ltd
- Rhizen Pharmaceuticals SA
- Rizen (Suzhou) Biosciences Co Ltd
- RNR BioMedical Inc
- Samyang Biopharmaceuticals Corp
- Sanofi
- Sapience Therapeutics Inc
- Scancell Holdings Plc
- Seagen Inc
- Seven and Eight Biopharmaceuticals Corp
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai GeneChem Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Institute of Biological Products Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Miracogen Inc
- Shanghai Xunhe Pharmaceutical Technology Co Ltd
- Shanghai Yihao Biotechnology Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shenyang Dongxing Pharmaceutical Co Ltd
- Shenzhen BinDeBio Ltd
- Shenzhen NeoCura Biotechnology Corp
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shijiazhuang Sagacity New Drug Development Co Ltd
- Shionogi & Co Ltd
- Simcere Pharmaceutical Group Ltd
- Simcha Therapeutics Inc
- Sino Biopharmaceutical Ltd
- SinoCelltech Group Ltd
- Smerud Medical Research International AS
- Soricimed Biopharma Inc
- Sorrento Therapeutics Inc
- Starpharma Holdings Ltd
- Steba Biotech SA
- Stemirna Therapeutics Ltd
- Stemsynergy Therapeutics Inc
- Supratek Pharma Inc
- Sutro Biopharma Inc
- Suzhou Hitebio Biotechnology Co Ltd
- Suzhou Medilink Therapeutics Ltd
- Suzhou Stainwei Biotech Inc
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Symphogen A/S
- Systimmune Inc
- T-Cure Bioscience Inc
- Tachyon Therapeutics Inc
- TAE Life Sciences LLC
- Taiho Oncology Inc
- Takara Bio Inc
- Takeda Pharmaceutical Co Ltd
- Telix Pharmaceuticals Ltd
- Tessa Therapeutics Ltd
- TOT Biopharm Co Ltd
- Transcenta Holding Ltd
- Transgene Biotek Ltd
- Transgene SA
- Turnstone Biologics Inc
- Tyg Oncology Ltd
- UCB SA
- United Immunity Co Ltd
- VM Discovery Inc
- Waterstone Hanxbio Pty Ltd
- Wuhan Binhui Biotechnology Co Ltd
- Xiangxue Life Sciences
- XuanZhu Biological Technology Co Ltd
- Zai Lab Ltd
- Zhuhai Beihai Biotech Co Ltd
- Zymeworks Inc
